Trial Watch: Dendritic cell-based interventions for cancer therapy

Erika Vacchelli, Ilio Vitale, Alexander Eggermont, Wolf Hervé Fridman, Jitka Fučíková, Isabelle Cremer, Jérôme Galon, Eric Tartour, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Dendritic cells (DCs) occupy a privileged position at the interface between innate and adaptive immunity, orchestrating a large panel of responses to both physiological and pathological cues. In particular, whereas the presentation of antigens by immature DCs generally results in the development of immunological tolerance, mature DCs are capable of priming robust, and hence therapeutically relevant, adaptive immune responses. In line with this notion, functional defects in the DC compartment have been shown to etiologically contribute to pathological conditions including (but perhaps not limited to) infectious diseases, allergic and autoimmune disorders, graft rejection and cancer. Thus, the possibility of harnessing the elevated immunological potential of DCs for anticancer therapy has attracted considerable interest from both researchers and clinicians over the last decade. Alongside, several methods have been developed not only to isolate DCs from cancer patients, expand them, load them with tumorassociated antigens and hence generate highly immunogenic clinical grade infusion products, but also to directly target DCs in vivo. This intense experimental effort has culminated in 2010 with the approval by the US FDA of a DC-based preparation (sipuleucel-T, Provenge®) for the treatment of asymptomatic or minimally symptomatic metastatic castration-refractory prostate cancer. As an update to the latest Trial Watch dealing with this exciting field of research (October 2012), here we summarize recent advances in DC-based anticancer regimens, covering both high-impact studies that have been published during the last 13 mo and clinical trials that have been launched in the same period to assess the antineoplastic potential of this variant of cellular immunotherapy

Original languageEnglish
Article numbere25771
JournalOncoImmunology
Volume2
Issue number10
DOIs
Publication statusPublished - 2013

Fingerprint

Dendritic Cells
Neoplasms
Therapeutics
Adaptive Immunity
Castration
Antigen Presentation
Graft Rejection
Cell- and Tissue-Based Therapy
Innate Immunity
Antineoplastic Agents
Immunotherapy
Cues
Communicable Diseases
Prostatic Neoplasms
Research Personnel
Clinical Trials
Antigens
Research

Keywords

  • Antigen-presenting cells
  • Immunogenic cell death
  • Monoclonal antibodies
  • Plasmacytoid dendritic cells
  • Regulatory T cells
  • Toll-like receptors

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Vacchelli, E., Vitale, I., Eggermont, A., Fridman, W. H., Fučíková, J., Cremer, I., ... Galluzzi, L. (2013). Trial Watch: Dendritic cell-based interventions for cancer therapy. OncoImmunology, 2(10), [e25771]. https://doi.org/10.4161/onci.25771

Trial Watch : Dendritic cell-based interventions for cancer therapy. / Vacchelli, Erika; Vitale, Ilio; Eggermont, Alexander; Fridman, Wolf Hervé; Fučíková, Jitka; Cremer, Isabelle; Galon, Jérôme; Tartour, Eric; Zitvogel, Laurence; Kroemer, Guido; Galluzzi, Lorenzo.

In: OncoImmunology, Vol. 2, No. 10, e25771, 2013.

Research output: Contribution to journalArticle

Vacchelli, E, Vitale, I, Eggermont, A, Fridman, WH, Fučíková, J, Cremer, I, Galon, J, Tartour, E, Zitvogel, L, Kroemer, G & Galluzzi, L 2013, 'Trial Watch: Dendritic cell-based interventions for cancer therapy', OncoImmunology, vol. 2, no. 10, e25771. https://doi.org/10.4161/onci.25771
Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fučíková J, Cremer I et al. Trial Watch: Dendritic cell-based interventions for cancer therapy. OncoImmunology. 2013;2(10). e25771. https://doi.org/10.4161/onci.25771
Vacchelli, Erika ; Vitale, Ilio ; Eggermont, Alexander ; Fridman, Wolf Hervé ; Fučíková, Jitka ; Cremer, Isabelle ; Galon, Jérôme ; Tartour, Eric ; Zitvogel, Laurence ; Kroemer, Guido ; Galluzzi, Lorenzo. / Trial Watch : Dendritic cell-based interventions for cancer therapy. In: OncoImmunology. 2013 ; Vol. 2, No. 10.
@article{666878ec68404027ac48da18234aedb8,
title = "Trial Watch: Dendritic cell-based interventions for cancer therapy",
abstract = "Dendritic cells (DCs) occupy a privileged position at the interface between innate and adaptive immunity, orchestrating a large panel of responses to both physiological and pathological cues. In particular, whereas the presentation of antigens by immature DCs generally results in the development of immunological tolerance, mature DCs are capable of priming robust, and hence therapeutically relevant, adaptive immune responses. In line with this notion, functional defects in the DC compartment have been shown to etiologically contribute to pathological conditions including (but perhaps not limited to) infectious diseases, allergic and autoimmune disorders, graft rejection and cancer. Thus, the possibility of harnessing the elevated immunological potential of DCs for anticancer therapy has attracted considerable interest from both researchers and clinicians over the last decade. Alongside, several methods have been developed not only to isolate DCs from cancer patients, expand them, load them with tumorassociated antigens and hence generate highly immunogenic clinical grade infusion products, but also to directly target DCs in vivo. This intense experimental effort has culminated in 2010 with the approval by the US FDA of a DC-based preparation (sipuleucel-T, Provenge{\circledR}) for the treatment of asymptomatic or minimally symptomatic metastatic castration-refractory prostate cancer. As an update to the latest Trial Watch dealing with this exciting field of research (October 2012), here we summarize recent advances in DC-based anticancer regimens, covering both high-impact studies that have been published during the last 13 mo and clinical trials that have been launched in the same period to assess the antineoplastic potential of this variant of cellular immunotherapy",
keywords = "Antigen-presenting cells, Immunogenic cell death, Monoclonal antibodies, Plasmacytoid dendritic cells, Regulatory T cells, Toll-like receptors",
author = "Erika Vacchelli and Ilio Vitale and Alexander Eggermont and Fridman, {Wolf Herv{\'e}} and Jitka Fuč{\'i}kov{\'a} and Isabelle Cremer and J{\'e}r{\^o}me Galon and Eric Tartour and Laurence Zitvogel and Guido Kroemer and Lorenzo Galluzzi",
year = "2013",
doi = "10.4161/onci.25771",
language = "English",
volume = "2",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Taylor and Francis Inc.",
number = "10",

}

TY - JOUR

T1 - Trial Watch

T2 - Dendritic cell-based interventions for cancer therapy

AU - Vacchelli, Erika

AU - Vitale, Ilio

AU - Eggermont, Alexander

AU - Fridman, Wolf Hervé

AU - Fučíková, Jitka

AU - Cremer, Isabelle

AU - Galon, Jérôme

AU - Tartour, Eric

AU - Zitvogel, Laurence

AU - Kroemer, Guido

AU - Galluzzi, Lorenzo

PY - 2013

Y1 - 2013

N2 - Dendritic cells (DCs) occupy a privileged position at the interface between innate and adaptive immunity, orchestrating a large panel of responses to both physiological and pathological cues. In particular, whereas the presentation of antigens by immature DCs generally results in the development of immunological tolerance, mature DCs are capable of priming robust, and hence therapeutically relevant, adaptive immune responses. In line with this notion, functional defects in the DC compartment have been shown to etiologically contribute to pathological conditions including (but perhaps not limited to) infectious diseases, allergic and autoimmune disorders, graft rejection and cancer. Thus, the possibility of harnessing the elevated immunological potential of DCs for anticancer therapy has attracted considerable interest from both researchers and clinicians over the last decade. Alongside, several methods have been developed not only to isolate DCs from cancer patients, expand them, load them with tumorassociated antigens and hence generate highly immunogenic clinical grade infusion products, but also to directly target DCs in vivo. This intense experimental effort has culminated in 2010 with the approval by the US FDA of a DC-based preparation (sipuleucel-T, Provenge®) for the treatment of asymptomatic or minimally symptomatic metastatic castration-refractory prostate cancer. As an update to the latest Trial Watch dealing with this exciting field of research (October 2012), here we summarize recent advances in DC-based anticancer regimens, covering both high-impact studies that have been published during the last 13 mo and clinical trials that have been launched in the same period to assess the antineoplastic potential of this variant of cellular immunotherapy

AB - Dendritic cells (DCs) occupy a privileged position at the interface between innate and adaptive immunity, orchestrating a large panel of responses to both physiological and pathological cues. In particular, whereas the presentation of antigens by immature DCs generally results in the development of immunological tolerance, mature DCs are capable of priming robust, and hence therapeutically relevant, adaptive immune responses. In line with this notion, functional defects in the DC compartment have been shown to etiologically contribute to pathological conditions including (but perhaps not limited to) infectious diseases, allergic and autoimmune disorders, graft rejection and cancer. Thus, the possibility of harnessing the elevated immunological potential of DCs for anticancer therapy has attracted considerable interest from both researchers and clinicians over the last decade. Alongside, several methods have been developed not only to isolate DCs from cancer patients, expand them, load them with tumorassociated antigens and hence generate highly immunogenic clinical grade infusion products, but also to directly target DCs in vivo. This intense experimental effort has culminated in 2010 with the approval by the US FDA of a DC-based preparation (sipuleucel-T, Provenge®) for the treatment of asymptomatic or minimally symptomatic metastatic castration-refractory prostate cancer. As an update to the latest Trial Watch dealing with this exciting field of research (October 2012), here we summarize recent advances in DC-based anticancer regimens, covering both high-impact studies that have been published during the last 13 mo and clinical trials that have been launched in the same period to assess the antineoplastic potential of this variant of cellular immunotherapy

KW - Antigen-presenting cells

KW - Immunogenic cell death

KW - Monoclonal antibodies

KW - Plasmacytoid dendritic cells

KW - Regulatory T cells

KW - Toll-like receptors

UR - http://www.scopus.com/inward/record.url?scp=84890254287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890254287&partnerID=8YFLogxK

U2 - 10.4161/onci.25771

DO - 10.4161/onci.25771

M3 - Article

AN - SCOPUS:84890254287

VL - 2

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 10

M1 - e25771

ER -